Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, USA.
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
Int J Mol Sci. 2020 Oct 22;21(21):7810. doi: 10.3390/ijms21217810.
CCN1 (cysteine-rich 61, connective tissue growth factor, and nephroblastoma-1), previously named CYR61 (cysteine-rich angiogenic inducer 61) belongs to the CCN family of matricellular proteins. CCN1 plays critical roles in the regulation of proliferation, differentiation, apoptosis, angiogenesis, and fibrosis. Recent studies have extensively characterized the important physiological and pathological roles of CCN1 in various tissues and organs. In this review, we summarize both basic and clinical aspects of CCN1 in pulmonary diseases, including acute lung injury (ALI), chronic obstructive pulmonary disease (COPD), lung fibrosis, pulmonary arterial hypertension (PAH), lung infection, and lung cancer. We also emphasize the important challenges for future investigations to better understand the CCN1 and its role in physiology and pathology, as well as the questions that need to be addressed for the therapeutic development of CCN1 antagonists in various lung diseases.
CCN1（富含半胱氨酸的 61 型、结缔组织生长因子和肾母细胞瘤-1），以前称为 CYR61（富含半胱氨酸的血管生成诱导因子 61），属于细胞外基质蛋白的 CCN 家族。CCN1 在调节增殖、分化、凋亡、血管生成和纤维化方面发挥着关键作用。最近的研究广泛描述了 CCN1 在各种组织和器官中的重要生理和病理作用。在这篇综述中，我们总结了 CCN1 在肺部疾病中的基础和临床方面，包括急性肺损伤（ALI）、慢性阻塞性肺疾病（COPD）、肺纤维化、肺动脉高压（PAH）、肺部感染和肺癌。我们还强调了未来研究的重要挑战，以更好地了解 CCN1 及其在生理学和病理学中的作用，以及为 CCN1 拮抗剂在各种肺部疾病中的治疗开发需要解决的问题。
Zotero 插件